Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 378

Earlier reports on the utility of peripheral blood as a resource for hematopoietic stem cells have resulted in studies to identify methods to increase the number of stem cells in this particular tissue. Mobilization of hematopoietic progenitor stem cells involves the stimulation of bone marrow cells to generate hematopoietic stem cells and inducing their release into circulation for subsequent collection via apheresis.

A recent clinical trial examined the effectiveness of using plerixafor (AMD3100), which is an immunostimulant that could synergistically act with the cytokine, granulocyte colony-stimulating factor (G-CSF). Plerixafor has been previously shown to be more effective in mobilizing hematopoietic progenitor cells compared to using G-CSF alone. Furthermore, the combinatorial use of plerixafor and G-CSF results in significantly higher expression levels of genes associated with tissue engraftment. The study included 31 patients positively diagnosed with multiple myeloma (MM) and 4 patients with non-Hodgkin’s lymphoma who underwent treatment with G-CSF at a concentration of 10 mg/kg each day for four consecutive days. By the end of the fourth day of treatment, plerixafor at a concentration of 0.24 mg/kg was administered, followed by apheresis the next day.

The specific regimen showed a 2.6-fold higher density of CD34+ cells in the peripheral blood relative to baseline cell counts. This treatment also resulted in minimal changes in the number of tumor cells in the peripheral blood in 22 percent of the patients, suggesting that this mobilization regimen did not significantly influence tumor status and, more importantly, it served as a new mobilization technique that resulted in a higher number of hematopoietic stem cells that could then be used for HSCT. No patients showed signs of graft failure and no adverse drug reactions were observed following the administration of plerixafor.